erythropoietinGenealiases: DBAL · ECYT5 · EP · MVCD2
Q-omics provides the consensus-scored EPO profile across patient tissues and cancer cell-line models. EPO expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, EPO is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, EPO protein abundance shows 20,011 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight HNSC, and PDAC as cancer lineages where EPO shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EPO — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EPO survival associations across molecular data types. EPO RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EPO RNA expression–survival associations across cancer types. High EPO expression shows unfavorable associations in LIHC, ACC, COAD and LGG, but favorable associations in HNSC and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for EPO RNA expression.
This table summarizes EPO tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for EPO. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EPO shows lower tumor expression in KIRP and KICH and higher tumor expression in HNSC, KIRC, BRCA and LUSC. The HNSC box plot shows higher EPO RNA expression in tumor versus normal tissue (log2 FC = +1.193, t-test p < 0.001).
This table shows molecular features associated with EPO in patient tissues and cancer cell lines. In patient samples, EPO shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, EPO RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
